As an alternative to DNA-based HRD tests, functional assays that assess the ability of replicating tumor cells to accumulate RAD51 protein at DNA DSBs were developed for use in breast, ovarian and endometrial cancer [28,29,30,31,32,33,34,35,36,37]. This evidence concerns the gene RAD51 and neoplasm.